Antiangiogenic Synergism of Integrin-Targeted Fumagillin Nanoparticles and Atorvastatin in Atherosclerosis
- 16 September 2008
- journal article
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 1 (5), 624-634
- https://doi.org/10.1016/j.jcmg.2008.06.003
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Minute dosages of ανβ3‐targeted fumagillin nanoparticles impair Vx‐2 tumor angiogenesis and development in rabbitsThe FASEB Journal, 2008
- In Vivo Atherosclerotic Plaque Characterization Using Magnetic Susceptibility Distinguishes Symptom-Producing PlaquesJACC: Cardiovascular Imaging, 2008
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- Imaging of Vx‐2 rabbit tumors with ανβ3‐integrin‐targeted 111In nanoparticlesInternational Journal of Cancer, 2007
- Statin Treatment Is Not Associated With Consistent Alterations in Inflammatory Status of Carotid Atherosclerotic PlaquesStroke, 2006
- Role of Angiogenesis in Cardiovascular DiseaseCirculation, 2005
- Detection of Injury-Induced Vascular Remodeling by Targeting Activated α v β 3 Integrin In VivoCirculation, 2004
- The Activation State of αvβ3Regulates Platelet and Lymphocyte Adhesion to Intact and Thrombin-cleaved OsteopontinPublished by Elsevier ,2000
- Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidasesJournal of Cellular Biochemistry, 2000
- Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470New England Journal of Medicine, 1998